Abstract
Immunotherapy has had a limited clinical benefit in pancreatic ductal adenocarcinoma (PDAC). In a pre-clinical mouse model of PDAC treated with glucocorticoid-induced TNFR-related protein (GITR) agonist, the tumours showed nondurable and heterogeneous responses to the GITR agonist. We hypothesised that resistance to GITR agonist is associated with a unique symbiotic interaction between persistent and emergent tumour clones resistant to therapy response.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
